Syncona-backed Achilles Therapeutics recommends voluntary liquidation, return capital to shareholders
LONDON: Syncona Ltd, a leading life science investor, announced Monday that its portfolio company, Achilles Therapeutics plc, has recommended a members’ solvent voluntary liquidation to...
Achilles Therapeutics prices its ADS at an IPO rate of $18
LONDON: Syncona Ltd’s portfolio company Achilles Therapeutics plc has announced the pricing of its initial public offering (IPO) in the United States of 9.75 million...